Category Reports Biotech

GLSI is exactly the kind of name that can look much cleaner in a press release than it does in real portfolio construction. The company has one lead asset, one pivotal clinical thesis, limited cash, ongoing need for financing, and a story that can produce violent stock reactions because the float is relatively small and the clinical promise is easy to narrate. That is why the most useful way to rebuild the article in the new format is to put the scientific signal and the financing reality in the same frame from the first page.

Olema sits in one of the most interesting transition zones in clinical-stage biotech. It is no longer a company that can be dismissed as little more than a speculative preclinical story, because it now has a late-stage development strategy centered on palazestrant, a second clinical engine in OP-3136, and a balance sheet that looks strong enough to bridge the company through several major milestones. At the same time, Olema is not yet a diversified oncology company with multiple independent late-stage assets that can absorb a major failure without a violent valuation reset. That is why the stock remains so fascinating. It offers a genuine setup for a re-rating if execution continues, but it also remains highly exposed to a narrow band of high-information events.

NRx Pharmaceuticals finally got the kind of news biotech traders usually wait for: not just another optimistic corporate interpretation, but formal written FDA minutes that document the regulatory path. In today’s release, the company said it received the confirmatory written minutes from its February 17, 2026 in-person Type C meeting with the FDA. According to NRx, those minutes support a path to file an NDA for NRX-100 by June 2026 using existing adequate and well-controlled clinical trial data together with confirmatory Real World Evidence. The company also said the FDA confirmed that no additional clinical trials and no bridging studies are required for the preservative-free formulation

A long-form bilingual deep dive built around the full regulatory arc of Aldeyra, from the first dry-eye filing to the 2025 collapse and the current March 2026 binary setup. The focus here is not only on what happened, but on why the market still cares, what could realistically change if reproxalap is approved, what the damage would look like if it is rejected again, and how retail traders are framing the setup in the final stretch before the decision.

Ocugen came back to life on a violent session after a stacked sell-side day: one firm initiated with an Outperform and a $10 target, while another raised its target to $22 from $15 and kept a Buy rating. But the move does not sit on analyst language alone. It lands on top of a Phase 3 enrollment-complete lead program, a visible BLA path, multiple ocular follow-on catalysts, a high-beta retail base, meaningful short interest, and a balance sheet that is improved from panic but still nowhere near bulletproof.

On March 10, 2026, Capricor Therapeutics announced that the FDA has lifted its Complete Response Letter (CRL) and resumed review of the Biologics License Application (BLA) for Deramiocel. The agency assigned a new PDUFA target action date of August 22, 2026—a pivotal moment after months of regulatory uncertainty.

PMV Pharmaceuticals is a precision oncology company built around rezatapopt (PC14586), an oral small-molecule reactivator of p53 designed for tumors harboring the TP53 Y220C mutation. The story matters because TP53 is one of the most important tumor suppressor genes in cancer biology, and because PMV has now moved from mechanism-only interest into clinically visible efficacy data. The company’s registrational PYNNACLE study has produced an overall 34% ORR across evaluable Phase 2 patients and a 46% ORR in the ovarian cohort at the September 4, 2025 cutoff, with the company later reporting a 50% ORR in the same ovarian cohort after that cutoff. FDA Orphan Drug Designation granted on March 2, 2026 adds meaningful regulatory support. PMV says it plans to submit an NDA in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation.